Celgene Corp. buy tamam
Start price
10.09.15
/
50%
€108.55
Target price
21.07.16
€117.26
Performance (%)
-13.06%
End price
21.07.16
€94.37
Summary
This prediction ended on 21.07.16 with a price of €94.37. The price of Celgene Corp. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -13.06%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Celgene Corp. | - | - | - | - |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
Comments by tamam for this prediction
In the thread Celgene Corp. diskutieren
Celgene: Time To Buy The Dip
The biotech sector has been hit hard in the recent sell-off in the overall markets. Major indices are down some 15% from recent highs; squarely in the correction territory.
The negative sentiment on this high beta sector of the market could last a while longer, but it is not too soon to start to accumulate the high quality names.
One of these is Celgene, which is down more than $20 a share from recent highs and offers a compelling combination of growth and value at these levels.
(Laufzeit überschritten)